# Agennix

Source: https://onco.cc/companies/agennix/  
OnCo record `agennix` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Agennix was a German-American biotech whose oral talactoferrin, a recombinant form of the milk protein lactoferrin, failed a phase 3 trial in non-small cell lung cancer.

## Summary

Agennix, founded in 1993 with operations in Princeton, New Jersey and Munich, developed talactoferrin alfa, a recombinant human lactoferrin taken by mouth as an immunotherapy. The phase 3 FORTIS-M trial in previously treated non-small cell lung cancer did not improve survival, and the company ceased operations. Its trials remain on ClinicalTrials.gov under Agennix as lead sponsor.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Agennix AG; Agennix Incorporated
- Tags: ctgov-sponsor
- HQ: Princeton, NJ
- Type: biotech
- Website: http://agennix.com

## Sources

- Official website: http://agennix.com
- ClinicalTrials.gov: trials led by Agennix AG: https://clinicaltrials.gov/search?lead=Agennix%20AG
- Wikidata: https://www.wikidata.org/wiki/Q30283567

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/agennix.json